PRPH

ProPhase Labs Inc.

Price

$0.06

return (12m)

-98.39%

p/e

-0.03

p/bv

-1.15

DIVIDEND YIELD

0.00%

PRPH price

ProPhase Labs

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment PRPH

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

-27.63%

3 months

-53.68%

1 year

-98.39%

2 years

-99.81%

5 years

-99.91%

10 years

-99.18%

Fundamentals PRPH

Valuation

P/E

-0.03

Sector -4.01

Industry -4.01

P/BV

-1.15

Sector 2.04

Industry 2.04

P/Revenue (PSR)

0.17

Sector -4.27

Industry -4.27

EV/EBITDA

-0.31

Sector -238.24

Industry -238.24

EV/EBIT

-0.21

Sector -670.52

Industry -670.52

P/EBITDA

-0.09

Sector -4.23

Industry -4.23

P/EBIT

-0.05

Sector -4.26

Industry -4.26

P/Total Assets

0.01

Sector 1.45

Industry 1.45

P/Net Current Assets

-0.01

Sector -13.26

Industry -13.26

P/Working Capital

-0.01

Sector -11.36

Industry -11.36

EPS

-1.99

Sector -2.20

Industry -2.20

BVPS

-0.05

Sector 1.95

Industry 1.95

Efficiency

Gross Margin

28.43%

Sector 36.28%

Industry 36.28%

EBITDA Margin

-187.18%

Sector -16,823.42%

Industry -16,823.42%

EBIT Margin

-269.23%

Sector -4,238,733.37%

Industry -4,238,733.37%

Operating Margin

-100.00%

Sector -38.78%

Industry -38.78%

Net Profit Margins

-100.00%

Sector -39.92%

Industry -39.92%

Asset Turnover

0.02

Sector 0.03

Industry 0.03

Profitability

ROE

3,914.75%

Sector -65.94%

Industry -65.94%

ROA

-40.66%

Sector -66.10%

Industry -66.10%

ROIC

-14.33%

Sector -2,918.74%

Industry -2,918.74%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

0.06

Sector 2.90

Industry 2.90

Net Debt / EBITDA

0.01

Sector -13,526,126.10

Industry -13,526,126.10

Net Debt / EBIT

0.01

Sector -3.64

Industry -3.64

Net Debt / Equity

0.05

Sector -1.10

Industry -1.10

Gross Debt / Equity

0.00

Sector -0.10

Industry -0.10

Equity/Assets

-0.01

Sector 0.42

Industry 0.42

Liabilities/Assets

1.01

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

-44.72%

Sector -

Industry -

5Y Earnings CAGR

0.00%

Sector -

Industry -

Fundamentals PRPH

DRAG THE FRAME TO SEE MORE DATA

Stock Comparison Tool

DRAG THE FRAME TO SEE MORE DATA

	p/e	p/bv	ROE	dy	market cap	net margin
PRPH	-0.03	-1.15	3,914.75%	0.00%	$703.20 K	-100.00%
JNJ	30.06	7.44	24.76%	1.99%	$632.34 B	21.48%
PFE	18.39	1.52	8.29%	7.11%	$137.74 B	11.83%
ABBV	126.05	-69.30	-54.98%	2.60%	$458.19 B	5.79%
NVO	11.48	6.93	60.40%	3.79%	$217.68 B	37.15%
MRK	36.33	7.07	19.45%	2.56%	$324.61 B	13.59%
AZN	25.14	5.51	21.93%	1.90%	$261.15 B	17.19%
GILD	17.54	6.90	39.33%	2.47%	$161.64 B	30.99%
BMY	17.28	6.25	36.19%	4.05%	$125.69 B	15.01%
ZTS	11.99	9.80	81.75%	2.74%	$31.69 B	27.79%
REGN	15.66	2.20	14.08%	0.55%	$69.27 B	29.65%
HALO	27.62	43.86	158.82%	0.00%	$9.63 B	23.13%
AMGN	26.05	22.11	84.87%	2.60%	$203.18 B	20.96%
MCK	21.59	-123.30	-570.98%	0.39%	$102.83 B	1.18%
VRTX	28.04	6.28	22.41%	0.00%	$121.66 B	35.51%
CAH	34.58	-20.13	-58.20%	0.89%	$53.78 B	0.62%
HRMY	14.10	2.26	16.00%	0.00%	$2.05 B	16.20%
BIIB	21.68	1.59	7.36%	0.00%	$29.75 B	13.81%
MEDP	34.42	38.99	113.29%	0.00%	$16.92 B	17.67%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

PRPH Historical Dividends

current DY: 0.00%

5-year average DY: 2.15%

DRAG THE FRAME TO SEE MORE DATA

type	Ex - Dividend Date	payment date	value
Dividends	05/23/2022	06/03/2022	3.00000000
Dividends	02/25/2022	03/10/2022	3.00000000
Dividends	05/21/2021	06/03/2021	3.00000000
Dividends	11/29/2019	12/12/2019	2.50000000
Dividends	01/08/2019	01/24/2019	2.50000000
Dividends	05/17/2018	06/05/2018	9.26300000
Dividends	05/17/2018	06/05/2018	10.00000000

ABOUT ProPhase Labs

ProPhase Labs Inc.

Average Investor10 user rating

4.0 (0 people)

United States

37 years

Founded: 1989

1995

Time since IPO - 31 years

95

Employees

ProPhase Labs Inc. (United States) is listed on the Nasdaq and has a market capitalization of $703.20 Thousand, with shareholders equity totaling $-610.00 Thousand.

The company employs approximately 95 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, ProPhase Labs Inc. reported $4.08 million in revenue, generating net income of $-23.88 million.

Key financial metrics include a P/E ratio of -0.03, a price-to-book (P/B) ratio of -1.15, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker PRPH.

Market cap

$703.20 Thousand

Net worth

$-610.00 Thousand

$-610,000.00

Assets

$58.73 million

$58,730,000.00

Total Shares Outstanding

12.00 million

12,000,000

Average Daily Trading Volume

$78.06 Thousand

$78,060.80

Sector

Health Care

Industry

Biotechnology

PRPH

PRPH revenue and profits

Financial Results PRPH

DRAG THE FRAME TO SEE MORE DATA

PRPH cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$859.49 23,63% (12M)

P/E

21.59

0.39%

ROE

-570.98%

P/BV

-123.30

CAH - Cardinal Health

$229.02 48,35% (12M)

P/E

34.58

0.89%

ROE

-58.20%

P/BV

-20.13

JNJ - Johnson & Johnson

$258.25 59,02% (12M)

P/E

30.06

1.99%

ROE

24.76%

P/BV

7.44

MRK - Merck & Co.

$130.85 70,49% (12M)

P/E

36.33

2.56%

ROE

19.45%

P/BV

7.07

AZN - AstraZeneca

$170.49 16,29% (12M)

P/E

25.14

1.90%

ROE

21.93%

P/BV

5.51

ABBV - AbbVie

$253.35 35,07% (12M)

P/E

126.05

2.60%

ROE

-54.98%

P/BV

-69.30

NVO - Novo Nordisk

$46.99 0,92% (12M)

P/E

11.48

3.79%

ROE

60.40%

P/BV

6.93

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$859.49 23,63% (12 M)

P/L

21.59

0.39%

ROE

-570.98%

P/VP

-123.30

CAH - Cardinal Health

$229.02 48,35% (12 M)

P/L

34.58

0.89%

ROE

-58.20%

P/VP

-20.13

JNJ - Johnson & Johnson

$258.25 59,02% (12 M)

P/L

30.06

1.99%

ROE

24.76%

P/VP

7.44

MRK - Merck & Co.

$130.85 70,49% (12 M)

P/L

36.33

2.56%

ROE

19.45%

P/VP

7.07

AZN - AstraZeneca

$170.49 16,29% (12 M)

P/L

25.14

1.90%

ROE

21.93%

P/VP

5.51

ABBV - AbbVie

$253.35 35,07% (12 M)

P/L

126.05

2.60%

ROE

-54.98%

P/VP

-69.30

NVO - Novo Nordisk

$46.99 0,92% (12 M)

P/L

11.48

3.79%

ROE

60.40%

P/VP

6.93

Frequently Asked Questions

What is the price of ProPhase Labs (PRPH) today?

A cotação de ProPhase Labs (PRPH) hoje está em US$ 0.06, com uma variação de -98.39% em relação ao último ano. A cotação de ProPhase Labs (PRPH) iniciou o ano negociando na casa dos US$ 0.45 e hoje está em US$ 0.06. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de ProPhase Labs (PRPH) e dados de ações do Ibovespa e mercados internacionais.

Quando ProPhase Labs (PRPH) paga dividendos?

ProPhase Labs (PRPH) não distribuiu dividendos no último ano.

Is ProPhase Labs (PRPH) a good investment?

Atualmente, ProPhase Labs (PRPH) está cotada a US$ 0.06, com um P/L de -0.03, representando um desvio de 89% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de -98.39 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de -98.39%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy ProPhase Labs (PRPH) stock?

Investir em ações de ProPhase Labs (PRPH) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of ProPhase Labs (PRPH) yield today?

A rentabilidade de ProPhase Labs (PRPH) foi de -27.63% no último mês, -98.39% no último ano e -99.91% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de ProPhase Labs (PRPH) hoje, o investimento total seria de US$ 5.79, com base na cotação atual de US$ 0.06.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 0.09
Em 5 anos: US$ 0.005211
Em 10 anos: US$ 0.05

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

PRPH

ProPhase Labs Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment PRPH

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

current DY: 0.00%

5-year average DY: 2.15%

type

Ex - Dividend Date

payment date

value

ABOUT ProPhase Labs

ProPhase Labs Inc.

United States

37 years

1995

95

PROFIT X PRICE PRPH

Financial Results PRPH

PRPH cash flow

Asset, Revenue and Profit Growth - PRPH

PRPH balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

MRK - Merck & Co.

AZN - AstraZeneca

ABBV - AbbVie

NVO - Novo Nordisk

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

MRK - Merck & Co.

AZN - AstraZeneca

ABBV - AbbVie

NVO - Novo Nordisk

Frequently Asked Questions